Corpus Intelligence IC Memo — DOCTORS HOSPITAL OF MANTECA 2026-04-26 15:42 UTC
IC Memo — DOCTORS HOSPITAL OF MANTECA
Investment Committee Memorandum | CA | 73 beds | Grade C | EBITDA uplift $8.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

DOCTORS HOSPITAL OF MANTECA

CCN 050118 | SAN JOAQUIN, CA | 73 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

DOCTORS HOSPITAL OF MANTECA is a 73-bed suburban community hospital in SAN JOAQUIN, CA with $114.1M in net patient revenue and a -0.1% operating margin. The hospital serves a payer mix of 26.5% Medicare, 7.6% Medicaid, and 65.9% commercial.

Thesis: Turnaround. Our ML models identify $8.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.1% to 7.2% (+736bps).

Net Revenue HCRIS$114.1M
Current EBITDA COMPUTED$-160K
Operating Margin COMPUTED-0.1%
Occupancy HCRIS54.7%
Revenue / Bed COMPUTED$1.6M
Net-to-Gross HCRIS8.0%
Distress Probability ML44.8%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
142
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -0.1% places it above the state median. Among 142 size-comparable peers (36-146 beds), the median margin is -5.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (36-146), prioritizing same-state peers. 142 hospitals in the comp set.

HospitalStateBedsRevenueMargin
DOCTORS HOSPITAL OF MANTECA (Target)CA73$114.1M-0.1%
CONTRA COSTA REGIONAL MEDICAL CA124$595.0M-29.2%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
KFH - ANTIOCHCA144$445.4M8.1%
KFH - VACAVILLECA144$415.3M7.1%
EDEN MEDICAL CENTERCA126$389.8M2.7%
KFH - REDWOOD CITYCA140$379.7M-4.5%
SUTTER SANTA ROSA REGIONAL HOSCA124$374.4M-0.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $8.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.4M+210bp18mo
Cost to Collect4.5%2.5%$2.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.4M+122bp9mo
Clean Claim Rate88.0%96.0%$73K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.4M
Cost to Collect
$2.3M
Denial Rate Reduction
$2.3M
A/R Days Reduction
$1.4M
Clean Claim Rate
$73K
Total EBITDA Uplift$8.4M
Current EBITDA$-160K
+ RCM Uplift+$8.4M
Pro Forma EBITDA$8.2M
Current Margin-0.1%
Pro Forma Margin7.2%
WC Released (1x)$4.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-246K$82.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-246K$91.1M0.00x-100.0%
Bull Case9.0x11.0x$-222K$118.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-222K$129.5M0.00x-100.0%
Bear Case11.0x10.0x$-271K$41.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-271K$45.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 142 hospitals with 36-146 beds
  • Same-state prioritization (n=143)
  • Comp margins: P25=-22.8% / P50=-5.1% / P75=3.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.